SCHEMBL3666062

SCHEMBL3666062

CS(=O)(=O)NC(=O)C1CCN(c2cc[c]cn2)C(C(N)=O)C1

nearest known ligand 0.33

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 1/20 0.31
CYP2C19 P33261 1/20 0.31
CTSS P25774 1/20 0.31
KDM4E B2RXH2 2/20 0.30
ABL1 P00519 1/20 0.30
LMNA P02545 1/20 0.30
PDE10A Q9Y233 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3665632 0.78 HRH4 (0.33)
SCHEMBL2791478 0.78 SYK (0.33) KDM4EABL1LMNA
SCHEMBL2744014 0.75 AR (0.40) KMT2A
SCHEMBL3669358 0.73 USP30 (0.30)
SCHEMBL3421527 0.73 AKR1C3 (0.35) KMT2AALDH1A1CTSSKDM4ELMNA
SCHEMBL3666600 0.71 JAK2 (0.34)
SCHEMBL3662349 0.71 AAK1 (0.35)
SCHEMBL3666149 0.71 PIK3CD (0.32)
SCHEMBL3668762 0.71 USP30 (0.34) CTSSKDM4EABL1LMNA
SCHEMBL3669780 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155687-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2010-02-24 EP disclosed
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-07-02 US disclosed
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-23 US disclosed
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors VIA PHARMACEUTICALS, INC. 2009-04-16 US disclosed
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-09 US disclosed
WO-2008141976-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT KMT2A 1379/4885ALDH1A1 573/4885CYP2C19 1081/4885
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT KMT2A 1379/4885ALDH1A1 573/4885CYP2C19 1081/4885
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT KMT2A 1379/4885ALDH1A1 573/4885CYP2C19 1081/4885
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT KMT2A 1379/4885ALDH1A1 573/4885CYP2C19 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.